Univariate analysis comparing patient demographic characteristics, pathologic features and stage between lung cancers staged in the 2 years before the COVID-19 pandemic and in the first year of the pandemic
| Variable | No. (%) of cases* | Standardized difference | Stochastic dominance | OR (95% CI) | |
|---|---|---|---|---|---|
| 2 years before pandemic n = 373 | First year of pandemic n = 129 | ||||
| No. of cases per 30 d, mean | 15.3 | 10.6 | NA | ||
| Age, median (IQR), yr | 70 (63–75) | 71 (64–76) | −0.050 | – | NA |
| Sex | |||||
| Female | 240 (64.3) | 73 (56.6) | 0.159 | 0.539 | 0.72 (0.48–1.09) |
| Male | 133 (35.7) | 56 (43.4) | 1.38 (0.92–2.08) | ||
| Histologic type | |||||
| Adenocarcinoma | 236 (63.3) | 89 (69.0) | 0.207 | – | 1.29 (0.84–1.98) |
| Squamous cell carcinoma | 70 (18.8) | 25 (19.4) | 1.04 (0.63–1.73) | ||
| Carcinoid | 36 (9.7) | 6 (4.7) | 0.46 (0.19–1.12) | ||
| Other | 31 (8.3) | 9 (7.0) | 0.83 (0.38–1.80) | ||
| Lymphovascular invasion | 57 (15.3) | 28 (21.7) | 0.166 | 0.532 | 1.53 (0.93–2.54) |
| Positive margin | 18 (4.8) | 5 (3.9) | 0.047 | 0.495 | 0.80 (0.29–2.21) |
| Stage | |||||
| I | 239 (65.1) | 83 (64.3) | – | 0.497 | NA |
| II | 72 (19.6) | 31 (24.0) | |||
| III + IV† | 56 (15.3) | 15 (11.6) | |||
| NA | 6 | 0 | |||